Abbott announced the U.S. FDA approval of the company’s Eterna spinal cord stimulation system, the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott’s proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence proven to reduce pain 23% more than traditional waveform technology approaches.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott price target raised to $125 from $114 at Citi
- Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
- Abbott board increases quarterly dividend 8.5% to 51c per share
- Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity
- Abbott put volume heavy and directionally bearish